KFDA advises labeling change of salcatonin medicines

Published: 2012-07-25 06:57:00

Updated: 2012-07-25 06:57:00

The Korea Food and Drug Administration said on Monday that it instructed 11 pharmaceutical companies producing salcatonin preparations to add the following statements to the package inserts of 14 salcatonin medicines: ‘withdrawal of Intranasal formulation for osteoporosis treatment’ and ‘restrict...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK